Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | GLA | P06280 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.98 |
| ▸ | HPGD | P15428 | 4/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | DRD1 | P21728 | 2/20 | 0.96 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | TP53 | P04637 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terazosin SCHEMBL1172921 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL8540346 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL5421873 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL29361818 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL5918282 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL3221979 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL9079964 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL9195360 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL9053035 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL8540336 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4945 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375376-A1 | STABLE ORAL LIQUID COMPOSITION OF TERAZOSIN | Novitium Pharma LLC (US) | 2025-12-11 | — | — | US | claimed |
| US-12427108-B2 | Stable oral liquid composition of terazosin | Novitium Pharma LLC (US) | 2025-09-30 | — | — | US | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| CN-119528888-A | Preparation method of small-granularity terazosin hydrochloride | 迪嘉药业集团股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| CN-118169271-A | Method for detecting alpha-adrenergic receptor blocker, SSRI and 5-ARIs and application thereof | 巴中市产品质量检验检测中心 | 2024-06-11 | — | — | CN | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| CN-117092227-A | Method for rapidly screening multiple veterinary drug residues in milk | 黑龙江飞鹤乳业有限公司 | 2023-11-21 | — | — | CN | claimed |
| EP-4259279-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-18 | — | — | EP | claimed |
| EP-0656885-A1 | SYNTHESIS OF 2-SUBSTITUTED QUINAZOLINE COMPOUNDS (SUCH AS TERAZOSIN) AND MEOBENTINE AND BETHANIDINE AND INTERMEDIATES THEREFOR | ACIC (CANADA) INC. (CA) | 1995-06-14 | — | — | EP | claimed |
| US-5362730-A | Solvent extraction for compounds for treatment of hypertension | ABBOTT LABORATORIES (US) | 1994-11-08 | — | — | US | claimed |
| WO-1994005628-A1 | SYNTHESIS OF 2-SUBSTITUTED QUINAZOLINE COMPOUNDS (SUCH AS TERAZOSIN) AND MEOBENTINE AND BETHANIDINE AND INTERMEDIATES THEREFOR | ACIC (CANADA) INC. (CA) | 1994-03-17 | — | — | WO | claimed |
| US-5268182-A | Coating contains ethyl cellulose or methyl methacrylate; plasticizer and detackifying agent | ABBOTT LABORATORIES (US) | 1993-12-07 | — | — | US | claimed |
| EP-0536329-A4 | R(+)-TERAZOSIN | — | 1993-05-19 | — | — | EP | claimed |
| US-5212176-A | Adrenergic blockers | ABBOTT LABORATORIES (US) | 1993-05-18 | — | — | US | claimed |
| EP-0536329-A1 | R(+)-TERAZOSIN. | ABBOTT LAB (US) | 1993-04-14 | — | — | EP | claimed |
| WO-1992000073-A1 | R(+)-TERAZOSIN | ABBOTT LABORATORIES (US) | 1992-01-09 | — | — | WO | claimed |
| EP-0430287-A2 | Sustained-release drug dosage units | ABBOTT LABORATORIES (US) | 1991-06-05 | — | — | EP | claimed |
| US-4251532-A | ANTIHYPERTENSIVE AGENT | ABBOTT LABORATORIES (US) | 1981-02-17 | — | — | US | claimed |